Latest News

Study Finds No Significant Effect of Low-Dose Oral Minoxidil on BP


 

TOPLINE:

Low-dose oral minoxidil (LDOM), used off-label to treat alopecia, does not significantly affect blood pressure (BP) in patients with alopecia, but is associated with a slight increase in heart rate and a 5% incidence of hypotensive symptoms.

METHODOLOGY:

  • Researchers conducted a systematic review and meta-analysis of 16 studies, which involved 2387 patients with alopecia (60.7% women) who received minoxidil, a vasodilator originally developed as an antihypertensive, at doses of 5 mg or less per day.
  • Outcomes included changes in mean arterial pressure, systolic BP, diastolic BP, and heart rate.
  • Mean differences were calculated between pretreatment and posttreatment values.

TAKEAWAY:

  • Hypotensive symptoms were reported in 5% patients, with no significant hypotensive episodes. About 1.8% patients experienced lightheadedness or syncope, 1.2% experienced dizziness, 0.9% had tachycardia, and 0.8% had palpitations.
  • LDOM did not significantly alter systolic BP (mean difference, –0.13; 95% CI, –2.67 to 2.41), diastolic BP (mean difference, –1.25; 95% CI, –3.21 to 0.71), and mean arterial pressure (mean difference, –1.92; 95% CI, –4.00 to 0.17).
  • LDOM led to a significant increase in heart rate (mean difference, 2.67 beats/min; 95% CI, 0.34-5.01), a difference the authors wrote would “likely not be clinically significant for most patients.”
  • Hypertrichosis was the most common side effect (59.6%) and reason for stopping treatment (accounting for nearly 35% of discontinuations).

IN PRACTICE:

“LDOM appears to be a safe treatment for alopecia with no significant impact on blood pressure,” the authors wrote, noting that the study “addresses gaps in clinical knowledge involving LDOM.” Based on their results, they recommended that BP and heart rate “do not need to be closely monitored in patients without prior cardiovascular risk history.”

SOURCE:

The study was led by Matthew Chen, BS, Stony Brook Dermatology in New York. It was published online in The Journal of the American Academy of Dermatology.

LIMITATIONS:

The studies included had small sample sizes and retrospective designs, which may limit the reliability of the findings. Additional limitations include the absence of control groups, a potential recall bias in adverse effect reporting, and variability in dosing regimens and BP monitoring.

DISCLOSURES:

The authors reported no external funding or conflicts of interest.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. A version of this article first appeared on Medscape.com.

Recommended Reading

Red hair in women linked to elevated CRP levels in Nurses’ Health Study
MDedge Cardiology
Gray hair goes away and squids go to space
MDedge Cardiology
Dermatologists embrace low-dose oral minoxidil as hair loss adjunctive therapy
MDedge Cardiology
Study evaluates features of alopecia areata in Hispanic/Latinx patients
MDedge Cardiology
Low-dose oral minoxidil for hair loss soars after NYT article
MDedge Cardiology
Low-dose oral minoxidil for female pattern hair loss: Benefits, impact on BP, heart rate evaluated
MDedge Cardiology
Review finds no CV or VTE risk signal with use of JAK inhibitors for skin indications
MDedge Cardiology
Survey finds oral minoxidil shortage in Washington-area pharmacies
MDedge Cardiology
Smoking Associated With Increased Risk for Hair Loss Among Men
MDedge Cardiology
Study Finds No Increased Cancer Risk With Spironolactone
MDedge Cardiology